Rinvoq XR Shortage Update: What Patients Need to Know in 2026

If you've been searching online for "Rinvoq XR shortage" or calling pharmacies to ask about upadacitinib availability, you deserve a straight answer. Here's the current status in 2026 — including what's really behind access difficulties and what you can do.

Is Rinvoq XR on the FDA Shortage List in 2026?

No. Rinvoq XR is not on the FDA drug shortage list as of 2026. The FDA maintains a publicly searchable list of medications in official shortage, and upadacitinib (Rinvoq XR) does not appear on it. AbbVie manufactures the drug continuously and supplies it through specialty pharmacy networks across the United States.

However, patients regularly report difficulties getting Rinvoq XR quickly or consistently. This isn't a shortage in the traditional manufacturing sense — it's an access barrier problem driven by the drug's specialty status, high cost, and complex insurance requirements.

Why Patients Can't Always Get Rinvoq XR When They Need It

The core access challenges for Rinvoq XR in 2026 include:

Prior authorization delays: Nearly all commercial and Medicare plans require prior authorization before covering Rinvoq XR. The review process can take days to weeks, and incomplete documentation can restart the process entirely.

Step therapy requirements: Most insurers require patients to try and fail at least one TNF inhibitor first. For new patients who haven't been through that process, this can add months to the timeline.

Specialty pharmacy routing: Rinvoq XR must be dispensed through specialty pharmacies, not standard retail pharmacies. This adds logistical steps that can delay the first fill.

Cost barriers: Without insurance coverage or a savings card, Rinvoq XR costs over $7,000 per month — making it inaccessible as a cash-pay medication for most patients.

Has Rinvoq XR Ever Been in an Official Shortage?

Unlike medications such as GLP-1 agonists (semaglutide/Ozempic) or ADHD medications (Adderall) that faced prolonged FDA-designated shortages in recent years, Rinvoq XR has not experienced a manufacturing shortage since its approval in 2019. AbbVie has not issued any supply alerts or temporary distribution restrictions for upadacitinib through 2026.

What Patients Should Do Right Now

If you're having trouble accessing Rinvoq XR, here are concrete steps to take:

Call AbbVie's support line: 1-800-2RINVOQ (1-800-274-6867). AbbVie has case managers and Insurance Specialists who can expedite your access and connect you with a specialty pharmacy.

Verify your PA status: If your prior authorization is pending, call your insurer's specialty pharmacy line directly. Ask for the current status and whether any additional documentation is needed.

Apply for the Rinvoq Complete Savings Card: Commercially insured patients can reduce their monthly cost to as little as $5. Visit rinvoq.com/resources/save-on-rinvoq-costs or call 1-800-274-6867.

Apply for patient assistance: If you're uninsured or underinsured, myAbbVieAssist may provide Rinvoq XR at no cost for up to 12 months. Reapplication is available as needed.

Use Medfinder (medfinder.com) to search real-time inventory at pharmacies near you. Medfinder checks which specialty and retail pharmacies have your specific dose in stock.

How to Protect Your Supply Going Forward

Once you have access established, protect it:

Set up automatic refills through your specialty pharmacy — don't wait until you run out

Renew your prior authorization 60 days before it expires (most PAs last 6–12 months)

Keep your prescriber's office updated on your insurance status — plan changes at the start of the year can reset your PA

Order a 90-day supply when possible to create a buffer

When Should I Ask My Doctor About Alternatives?

If you've exhausted all access pathways and still can't obtain Rinvoq XR within 2 weeks, talk to your prescriber about temporary alternatives. See our guide on alternatives to Rinvoq XR for condition-specific options.

Also read: How to find Rinvoq XR in stock near you — tools and tips